Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
Emerge Phase 3 study podium poster to be featured in “Latest Discoveries & Emerging Trends in MDD” session
New epidemiological research on risks associated with anxiety and depression plus five posters across clinical program
Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced six poster presentations at the Psych Congress taking place September 15 through 19 in New Orleans, LA.
“This year at Psych Congress, we will share clinical findings from our DT120 Orally Disintegrating Tablet Phase 3 clinical development program in GAD and MDD, reflecting the broad potential of DT120 in the two largest psychiatric disorders,” said Dan Karlin, Chief Medical Officer, Definium Therapeutics. “We also will present new epidemiological research examining suicidal ideation in anxiety, depression, and comorbid populations, adding to the growing body of research needed to better understand suicide risk. We are proud to contribute to this important conversation during National Suicide Prevention Awareness Month.”
